5D Library › Biomathematical Models of Sub-Perceptual Tryptamine Pharmacokinetics, 5-HT2A Receptor Desensitisation and Neuroplastic Window Dynamics · 中文
Chapter 2. Prodrugs and Saturable Conversion: Saturation Blunts the Peak
The concept, and the part that is known
Some compounds in this class exist as prodrugs: the molecule itself has low activity and is converted in the body to an active species.
Evidence
Dephosphorylation (tissue homogenates and humans). Psilocybin is a phosphate ester, dephosphorylated in the body to psilocin. Horita and Weber demonstrated this enzymic dephosphorylation and the subsequent oxidation in mammalian tissue homogenates in 1961 (Horita and Weber 1961); Dinis-Oliveira reviewed the metabolism of psilocybin and psilocin and its forensic toxicological relevance (Dinis-Oliveira 2017). On human pharmacokinetics, Brown and colleagues conducted an escalating-dose study in healthy adults and reported the plasma concentration-time characteristics of psilocin (Brown et al. 2017).
Note
What this chapter does not handle. It discusses only the mathematical structure of the conversion step. It gives no mass, concentration, amount or conversion factor for any compound, does not discuss source, purity or preparation, and does not compare the potency of different compounds. Every value is dimensionless, relative to an unspecified reference.
The acetylated prodrugs — the class referred to by “prodrug deacetylation” in the book’s subtitle — are a different matter.
Evidence
Human conversion kinetics: none found. Tryptamines among new psychoactive substances have been reviewed, but chiefly in terms of analytical chemistry, epidemiology and toxicological case reports (Tittarelli et al. 2015). The literature search for this book found no published measurement of human deacetylation kinetics (, or equivalent) for the acetylated prodrugs. The model parameters in this chapter are therefore assumed values. A reader who knows of published human conversion kinetics is invited to say so through the 5D Library website.
Michaelis–Menten kinetics and two regimes
Writing for the prodrug concentration and for the active species, with conversion catalysed by a saturable enzyme (Johnson and Goody 2011):
When the conversion rate is approximately , first order; when it approaches , zero order — saturated.
Calculation
# Chapter 2. A prodrug converted by a saturable enzyme, in dimensionless
# units. An ester prodrug A is hydrolysed to the active species P, which is
# then eliminated:
# dA/dt = -Vmax A / (Km + A) - ka_loss A
# dP/dt = +Vmax A / (Km + A) - kel P
# Concentrations are in units of Km_ref (an arbitrary reference), time in
# units of the elimination half-life of P. NO mass, dose, product, route or
# source appears anywhere in this book; D below is a dose FRACTION relative to
# an unspecified reference exposure. The point is a distinction that is easy
# to get wrong. Saturation of the converting step does NOT make total exposure
# disproportionate: almost all of the prodrug converts eventually either way,
# and mass balance fixes the area under the curve. What saturation changes is
# the SHAPE - the peak and the time to peak - because a saturated enzyme works
# at a fixed rate and spreads the same total conversion over a longer time. So
# the common claim that a saturable prodrug step makes exposure "jump" at
# higher amounts is wrong for total exposure and right for the peak. Which
# regime applies depends on Km, which for the compounds at issue has not been
# measured in humans (Chapter 2 text).
import math
DT, T_END = 0.001, 12.0
KEL = math.log(2.0) # time unit = elimination half-life of P
KA_LOSS = 0.05 # competing loss of unconverted prodrug
def simulate(D, Km, Vmax=1.0):
A, P = D, 0.0
peak, tpeak, auc = 0.0, 0.0, 0.0
n = int(T_END / DT)
for i in range(n):
conv = Vmax * A / (Km + A)
dA = -conv - KA_LOSS * A
dP = conv - KEL * P
A = max(0.0, A + DT * dA)
P = max(0.0, P + DT * dP)
auc += P * DT
if P > peak:
peak, tpeak = P, (i + 1) * DT
return peak, tpeak, auc
if __name__ == "__main__":
print(
"Dimensionless prodrug model. Time unit = elimination half-life of"
" the active"
)
print(
"species; concentrations in units of a reference Km. D is a dose"
" FRACTION.\n"
)
print("A. Km = 10 (prodrug far below saturation: first-order regime)")
print(" D Cmax Tmax AUC AUC / D")
base = None
for D in (0.1, 0.2, 0.5, 1.0, 2.0, 5.0):
pk, tp, auc = simulate(D, Km=10.0)
print(
" {:6.2f} {:9.4f} {:9.3f} {:9.4f} {:9.4f}".format(
D, pk, tp, auc, auc / D
)
)
print(
"\nB. Km = 0.05 (enzyme saturated at these amounts: zero-order"
" regime)"
)
print(" D Cmax Tmax AUC AUC / D")
for D in (0.1, 0.2, 0.5, 1.0, 2.0, 5.0):
pk, tp, auc = simulate(D, Km=0.05)
print(
" {:6.2f} {:9.4f} {:9.3f} {:9.4f} {:9.4f}".format(
D, pk, tp, auc, auc / D
)
)
print(
"\nAUC / D is nearly constant in BOTH regimes, and that is the first"
" thing to"
)
print(
"notice: saturating the converting enzyme does not make total"
" exposure jump,"
)
print(
"because mass balance fixes it - almost all the prodrug converts"
" either way."
)
print("What saturation changes is the shape:")
for Km in (10.0, 0.05):
r1 = simulate(0.5, Km)
r2 = simulate(5.0, Km)
print(
" Km = {:5.2f}: tenfold D raises Cmax x {:.2f} and Tmax"
" x {:.2f}".format(Km, r2[0] / r1[0], r2[1] / r1[1])
)
print(
" Unsaturated, a tenfold rise in D raises the peak almost"
" tenfold and"
)
print(
" barely moves its timing. Saturated, the peak rises only 3.5-fold"
" while"
)
print(
" the time to peak stretches more than sixfold: the same total"
" amount is"
)
print(
" delivered more slowly and more flatly. So a saturable step"
" BLUNTS the"
)
print(
" peak rather than amplifying exposure - the opposite of what the"
" common"
)
print(" account of prodrug saturation suggests.")
print(
"\nC. The quantity that is NOT known: Km. Sweeping it over three"
" orders of"
)
print("magnitude at a FIXED dose fraction D = 1.0:")
print(
" Km Cmax Tmax AUC fraction of prodrug"
" converted"
)
for Km in (0.01, 0.05, 0.2, 1.0, 5.0, 20.0):
pk, tp, auc = simulate(1.0, Km)
# mass balance: AUC*kel = total P formed
conv_frac = auc * KEL
print(" {:7.2f} {:9.4f} {:9.3f} {:9.4f} {:20.3f}"
.format(Km, pk, tp, auc, conv_frac))
lo = simulate(1.0, 0.01)
hi = simulate(1.0, 20.0)
print(
"\n Across that range Cmax varies by a factor of {:.2f} and Tmax by"
" {:.2f},".format(
max(lo[0], hi[0]) / min(lo[0], hi[0]),
max(lo[1], hi[1]) / min(lo[1], hi[1]),
)
)
print(
" at the SAME dose fraction. So without a measured Km the model"
" cannot"
)
print(
" predict either the peak or its timing, even in these arbitrary"
" units."
)
print(
" Chapter 2 argues that this is the actual state of knowledge"
" for the"
)
print(
" prodrugs in question: no published human conversion kinetics"
" exist, so"
)
print(
" any such curve is parameterised by assumption, not by"
" measurement."
)
# Dimensionless prodrug model. Time unit = elimination half-life of the active
# species; concentrations in units of a reference Km. D is a dose FRACTION.
#
# A. Km = 10 (prodrug far below saturation: first-order regime)
# D Cmax Tmax AUC AUC / D
# 0.10 0.0094 2.830 0.0756 0.7565
# 0.20 0.0187 2.844 0.1508 0.7539
# 0.50 0.0458 2.882 0.3732 0.7463
# 1.00 0.0890 2.945 0.7338 0.7338
# 2.00 0.1681 3.065 1.4194 0.7097
# 5.00 0.3595 3.389 3.2157 0.6431
#
# B. Km = 0.05 (enzyme saturated at these amounts: zero-order regime)
# D Cmax Tmax AUC AUC / D
# 0.10 0.0855 0.268 0.1435 1.4351
# 0.20 0.1651 0.362 0.2863 1.4316
# 0.50 0.3731 0.641 0.7105 1.4210
# 1.00 0.6378 1.093 1.4038 1.4038
# 2.00 0.9658 1.945 2.7420 1.3710
# 5.00 1.3035 4.100 6.4128 1.2826
#
# AUC / D is nearly constant in BOTH regimes, and that is the first thing to
# notice: saturating the converting enzyme does not make total exposure jump,
# because mass balance fixes it - almost all the prodrug converts either way.
# What saturation changes is the shape:
# Km = 10.00: tenfold D raises Cmax x 7.84 and Tmax x 1.18
# Km = 0.05: tenfold D raises Cmax x 3.49 and Tmax x 6.40
# Unsaturated, a tenfold rise in D raises the peak almost tenfold and
# barely moves its timing. Saturated, the peak rises only 3.5-fold while
# the time to peak stretches more than sixfold: the same total amount is
# delivered more slowly and more flatly. So a saturable step BLUNTS the
# peak rather than amplifying exposure - the opposite of what the common
# account of prodrug saturation suggests.
#
# C. The quantity that is NOT known: Km. Sweeping it over three orders of
# magnitude at a FIXED dose fraction D = 1.0:
# Km Cmax Tmax AUC fraction of prodrug converted
# 0.01 0.6875 1.013 1.4066 0.975
# 0.05 0.6378 1.093 1.4038 0.973
# 0.20 0.5388 1.262 1.3936 0.966
# 1.00 0.3460 1.701 1.3407 0.929
# 5.00 0.1474 2.524 1.0290 0.713
# 20.00 0.0502 3.329 0.4559 0.316
#
# Across that range Cmax varies by a factor of 13.68 and Tmax by 3.29,
# at the SAME dose fraction. So without a measured Km the model cannot
# predict either the peak or its timing, even in these arbitrary units.
# Chapter 2 argues that this is the actual state of knowledge for the
# prodrugs in question: no published human conversion kinetics exist, so
# any such curve is parameterised by assumption, not by measurement.The program’s result differs from the common account, and that is the point of the chapter.
The common account is that saturating the prodrug conversion makes exposure “jump”, so that a small increase in amount can be dangerous. In this model that is false. Look at the AUC-per-amount column in sections A and B: it is nearly constant in both regimes. The reason is mass balance — almost all of the prodrug converts eventually (the last column of section C gives the converted fraction) — and the area under the curve is set by the total amount converted and the clearance, not by the rate of conversion.
What saturation changes is the shape. Unsaturated, a tenfold amount raises the peak 7.84-fold and barely moves the time to peak (1.18-fold); saturated, the peak rises only 3.49-fold while the time to peak stretches 6.40-fold. That is:
a saturable prodrug step delivers the same total amount more slowly and more flatly. It blunts the peak; it does not amplify exposure.
Note
This does not say saturation is unimportant. The peak and the time to peak are quite likely more relevant to the intensity of a subjective experience and to how onset feels (Chapter 3 shows the time course of an effect is also governed by ke0). The chapter’s point is only that which quantity saturation changes is commonly stated backwards. An argument that “increasing the amount is risky” cannot rest on “saturated conversion makes exposure jump”, because that does not hold in this model.
The cost of not knowing the Michaelis constant
Section C sweeps over three orders of magnitude at a fixed amount. The peak varies by a factor of 13.68 and the time to peak by 3.29. So without a measured the model can predict neither the peak nor its timing, even in these arbitrary units.
Could be recovered from published data? The next program answers that, and the answer is unexpectedly positive.
Calculation
# Chapter 2. Can Vmax and Km be recovered from measurements of the ACTIVE
# species alone? This is the practical question for any attempt to
# parameterise the model of p02 from published data, because the prodrug
# itself is usually not assayed. The program fits the two-parameter conversion
# model to a synthetic concentration-time curve of P (sampled at realistic
# times, with 10 % proportional noise) by grid search on the sum of squares,
# and reports the set of (Vmax, Km) pairs that fit within the noise. If that
# set spans orders of magnitude, the parameters are practically unidentifiable
# from such data. Dimensionless units throughout; synthetic data; fixed seed;
# standard library only.
import math
import random
DT, T_END = 0.002, 12.0
KEL = math.log(2.0)
KA_LOSS = 0.05
SAMPLE_T = [0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0]
NOISE = 0.10
def curve(D, Km, Vmax):
A, P = D, 0.0
out, want, k = [], sorted(SAMPLE_T), 0
n = int(T_END / DT)
for i in range(n):
t = (i + 1) * DT
conv = Vmax * A / (Km + A)
A = max(0.0, A + DT * (-conv - KA_LOSS * A))
P = max(0.0, P + DT * (conv - KEL * P))
while k < len(want) and t >= want[k] - DT / 2:
out.append(P)
k += 1
while len(out) < len(SAMPLE_T):
out.append(P)
return out
TRUE_KM, TRUE_VMAX, D = 0.30, 1.00, 1.0
def ssq(obs, pred):
return math.fsum((a - b) ** 2 for a, b in zip(obs, pred))
if __name__ == "__main__":
rng = random.Random(5202)
truth = curve(D, TRUE_KM, TRUE_VMAX)
obs = [v * (1.0 + rng.gauss(0.0, NOISE)) for v in truth]
print(
"Truth: Km = {:.2f}, Vmax = {:.2f}. {} samples, {:.0%} proportional"
" noise.".format(TRUE_KM, TRUE_VMAX, len(SAMPLE_T), NOISE)
)
print("Observed active-species curve:")
for a, b in ((0, 5), (5, len(SAMPLE_T))):
print(
" t " + "".join("{:8.2f}".format(t) for t in SAMPLE_T[a:b])
)
print(" P " + "".join("{:8.4f}".format(v) for v in obs[a:b]))
kms = [0.01 * (10 ** (0.1 * k)) for k in range(41)] # 0.01 .. 100
vms = [0.1 * (10 ** (0.05 * k)) for k in range(41)] # 0.1 .. 10
best, grid = None, []
for Km in kms:
for Vm in vms:
s = ssq(obs, curve(D, Km, Vm))
grid.append((s, Km, Vm))
if best is None or s < best[0]:
best = (s, Km, Vm)
s0, km0, vm0 = best
print(
"\nBest fit: Km = {:.3f}, Vmax = {:.3f} (SSQ {:.3e})".format(
km0, vm0, s0
)
)
# all pairs within an F-like tolerance of the optimum: a 2-parameter
# confidence region
tol = s0 * (1.0 + 2.0 * 2.0 / (len(SAMPLE_T) - 2))
inside = [(Km, Vm) for s, Km, Vm in grid if s <= tol]
kmin = min(k for k, _ in inside)
kmax = max(k for k, _ in inside)
vmin = min(v for _, v in inside)
vmax_ = max(v for _, v in inside)
print(
"Pairs fitting within the noise tolerance: {} of {}".format(
len(inside), len(grid)
)
)
print(" Km spans {:.3f} to {:.3f} (a factor of {:.0f})"
.format(kmin, kmax, kmax / kmin))
print(" Vmax spans {:.3f} to {:.3f} (a factor of {:.1f})"
.format(vmin, vmax_, vmax_ / vmin))
print(
"\nWhat those extremes predict for a FIVEFOLD larger dose fraction:"
)
print(" Km Vmax Cmax(D=5) AUC(D=5)")
def summarise(Km, Vm, Dd):
A, P, peak, auc = Dd, 0.0, 0.0, 0.0
for i in range(int(T_END / DT)):
conv = Vm * A / (Km + A)
A = max(0.0, A + DT * (-conv - KA_LOSS * A))
P = max(0.0, P + DT * (conv - KEL * P))
auc += P * DT
peak = max(peak, P)
return peak, auc
rows = []
for Km, Vm in ((km0, vm0), (kmin, min(v for k, v in inside if k == kmin)),
(kmax, max(v for k, v in inside if k == kmax))):
pk, au = summarise(Km, Vm, 5.0)
rows.append((pk, au))
print(" {:7.3f} {:8.3f} {:11.4f} {:10.4f}".format(Km, Vm, pk, au))
cmax_spread = max(r[0] for r in rows) / min(r[0] for r in rows)
auc_spread = max(r[1] for r in rows) / min(r[1] for r in rows)
print(
"\n Curves indistinguishable at D = 1 predict Cmax at D = 5"
" differing by a"
)
print(
" factor of only {:.2f} and AUC by {:.2f}.".format(
cmax_spread, auc_spread
)
)
print(
"\nThat is a POSITIVE result, and it has to be reported as one. Km"
" itself is"
)
print(
"recovered only to within a factor of {:.0f}, but the predictions"
" that matter".format(kmax / kmin)
)
print("are robust to that ignorance, because mass balance pins the total")
print("conversion whatever the enzyme's affinity. So structural")
print(
"non-identifiability is NOT the obstacle here: given one decent human"
)
print(
"concentration-time curve, extrapolating exposure to a nearby amount"
)
print("would be sound to within tens of per cent.")
print(
"\nThe obstacle is that there is no such curve to fit. Compare"
" the two"
)
print("situations directly, both at a fivefold larger dose fraction:")
def spread_over_km_prior(Dd, kms_prior):
vals = [summarise(k, 1.0, Dd) for k in kms_prior]
pk = [v[0] for v in vals]
return max(pk) / min(pk)
no_data = spread_over_km_prior(5.0, [0.01, 0.05, 0.2, 1.0, 5.0, 20.0])
print(
" with one fitted curve: Cmax uncertain by a factor of"
" {:.2f}".format(cmax_spread)
)
print(" with no data, Km only bounded")
print(
" to three orders of magnitude: Cmax uncertain by a factor of"
" {:.2f}".format(no_data)
)
print(
"\n The second number is the real state of knowledge for the"
" prodrugs at"
)
print(
" issue: no published human conversion kinetics exist, so the curve"
" is not"
)
print(
" poorly constrained by data, it is unconstrained by data. The"
" remedy is a"
)
print(
" measurement, not a better estimator - and until one exists,"
" statements of"
)
print(
" the form 'at a fraction of the usual exposure the kinetics are"
" linear'"
)
print(" are assumptions about Km rather than findings.")
# Truth: Km = 0.30, Vmax = 1.00. 10 samples, 10% proportional noise.
# Observed active-species curve:
# t 0.25 0.50 0.75 1.00 1.50
# P 0.1836 0.2445 0.4348 0.4349 0.5006
# t 2.00 3.00 4.00 6.00 8.00
# P 0.4044 0.1993 0.1063 0.0276 0.0064
#
# Best fit: Km = 0.316, Vmax = 1.000 (SSQ 6.379e-03)
# Pairs fitting within the noise tolerance: 18 of 1681
# Km spans 0.050 to 0.631 (a factor of 13)
# Vmax spans 0.708 to 1.259 (a factor of 1.8)
#
# What those extremes predict for a FIVEFOLD larger dose fraction:
# Km Vmax Cmax(D=5) AUC(D=5)
# 0.316 1.000 1.1475 6.3330
# 0.050 0.708 0.9577 6.1331
# 0.631 1.259 1.2506 6.4194
#
# Curves indistinguishable at D = 1 predict Cmax at D = 5 differing by a
# factor of only 1.31 and AUC by 1.05.
#
# That is a POSITIVE result, and it has to be reported as one. Km itself is
# recovered only to within a factor of 13, but the predictions that matter
# are robust to that ignorance, because mass balance pins the total
# conversion whatever the enzyme's affinity. So structural
# non-identifiability is NOT the obstacle here: given one decent human
# concentration-time curve, extrapolating exposure to a nearby amount
# would be sound to within tens of per cent.
#
# The obstacle is that there is no such curve to fit. Compare the two
# situations directly, both at a fivefold larger dose fraction:
# with one fitted curve: Cmax uncertain by a factor of 1.31
# with no data, Km only bounded
# to three orders of magnitude: Cmax uncertain by a factor of 6.13
#
# The second number is the real state of knowledge for the prodrugs at
# issue: no published human conversion kinetics exist, so the curve is not
# poorly constrained by data, it is unconstrained by data. The remedy is a
# measurement, not a better estimator - and until one exists, statements of
# the form 'at a fraction of the usual exposure the kinetics are linear'
# are assumptions about Km rather than findings.The result has two layers. First: fitting from a single exposure’s active-species concentration-time curve (10 sampling points, 10 % proportional noise), is pinned only to within a factor of 13 and to within 1.8. On that alone the parameters are poorly determined.
The second layer is the point: those curves, indistinguishable at , predict peaks at that differ by only a factor of 1.31 and areas by 1.05. The reason is again mass balance: whatever the enzyme’s affinity, the total converted is constrained. So
structural non-identifiability is not the obstacle here. With one decent human concentration-time curve to fit, extrapolating exposure to a nearby amount would be accurate to within tens of per cent.
The real obstacle is that there is no such curve. The program’s last section sets the two situations side by side: with a fitted curve the peak uncertainty is a factor of 1.31; with no data and bounded only to three orders of magnitude, it is 6.13. The second figure is the actual state of knowledge for this class of prodrug.
Note
Why the positive result is reported. Following Volume 33’s position, results are reported whether or not they support the author’s framework. This one counts against the pessimistic verdict that the model is unusable: it is usable, given one measurement. Writing it up as “the parameters are unidentifiable, so nothing can be said” would be a more dramatic but false conclusion — and false pessimism is as harmful as false optimism, because it suggests the problem is unsolvable in principle and so discourages making the measurement that would in fact solve it.
Hypothesis · not established
The author’s hypothesis (not established): for the acetylated prodrugs, human deacetylation is first order over the exposure range discussed here (that is, ), so active-species exposure is approximately proportional to the amount of prodrug and the time to peak is largely independent of it. What would show it to be wrong: in a human pharmacokinetic study conducted under regulatory authorisation, finding that the time to peak lengthens systematically with amount — for instance, that the lower bound of the 95 % confidence interval for the ratio of times to peak between highest and lowest groups exceeds 1.5. Note that the hypothesis makes no judgement about any amount; it is a claim about the functional form of the kinetics.
Summary
The dephosphorylation of psilocybin has had tissue-homogenate evidence since 1961, its metabolism has been reviewed, and human pharmacokinetics has an escalating-dose study. No published human conversion kinetics for the acetylated prodrugs were found, so the Michaelis parameters here are assumed values. The model gives a result running opposite to the common account: saturating the prodrug step does not make total exposure jump — mass balance fixes the area under the curve — but blunts the peak and extends the time to peak (at a tenfold amount: unsaturated, peak ×7.84 and time to peak ×1.18; saturated, peak ×3.49 and time to peak ×6.40). Without knowing , the peak at a fixed amount is uncertain by a factor of 13.68. But fitting from a single exposure’s curve yields a positive result: although is pinned only to within a factor of 13, the predicted peak at fivefold exposure differs by only 1.31, because mass balance constrains total conversion. The obstacle is therefore not non-identifiability but the absence of a curve to fit, where the peak uncertainty is 6.13.
References
Fan, Y. (2026). Biomathematical Models of Sub-Perceptual Tryptamine Pharmacokinetics, 5-HT2A Receptor Desensitisation and Neuroplastic Window Dynamics: From Michaelis–Menten Kinetics of Prodrug Deacetylation and Whole-Brain Connectivity Entropy to the Microdose Tolerance Ratchet, with a Textual Examination of the Dose Boundary in the Classical Materia Medica [亚知觉色胺药代动力学、5-HT2A 受体脱敏与神经可塑性窗口的生物数学模型] (Version 1.0.0). 5D Library. https://doi.org/10.5281/zenodo.24019347 · Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).